Jiangxi Jimin Kexin Pharmaceutical

Jimin Kexin is a leading Chinese pharmaceutical group headquartered in Nanchang, specializing in the development, manufacturing, and commercialization of innovative medicines and traditional Chinese treatments. Founded in 1999, the company has established a robust R&D infrastructure with major centers in Shanghai and Nanchang, focusing on therapeutic areas such as oncology, nephrology, cardiovascular, and infectious diseases. Jimin Kexin is recognized for its successful transition into a modern biotech innovator, highlighted by significant global out-licensing deals for its proprietary small molecules and biologics. Notable collaborations include partnerships with Genentech for an androgen receptor degrader and Orion Corporation for a KRAS G12C inhibitor. The company operates multiple state-of-the-art manufacturing facilities and maintains a dominant market presence in China while expanding its international footprint.